News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|February 1, 2004

Why does this boy refuse a genital exam?

Q A large, prepubescent 11-year-old boy came in for a school examination, after not having been in my office for three years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA expands TOFIDENCE (tocilizumab-bavi) indications to include CAR T-cell–induced CRS and pediatric COVID-19

FDA expands TOFIDENCE (tocilizumab-bavi) indications to include CAR T-cell–induced CRS and pediatric COVID-19

ByMorgan Ebert, Executive Editor

June 10th 2026

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

ByMorgan Ebert, Executive Editor

June 10th 2026

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

ByMorgan Ebert, Executive Editor

June 10th 2026

New sunscreen ingredient clears FDA for the first time since the 1990s

New sunscreen ingredient clears FDA for the first time since the 1990s

ByMorgan Ebert, Executive Editor

June 9th 2026

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

ByMorgan Ebert, Executive Editor

June 9th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

New sunscreen ingredient clears FDA for the first time since the 1990s

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

Earlier egg introduction guidelines linked to measurable decline in infant egg allergy prevalence